Hengrui Medicine Posts Net Profit of 6.9 Billion Yuan in First Three Quarters, Innovative Drug Revenue Share Rises to 65%
nashnova research
Hengrui Medicine (01276) reported net profit of RMB 6.923 billion for the first three quarters, up 20.38% year-on-year — far outpacing revenue growth of 5.26%, signalling a rapid shift toward higher-margin innovative drugs.
Why is profit growing four times faster than revenue?
Revenue reached RMB 24.409 billion, up 5.26% YoY; net profit hit RMB 6.923 billion, up 20.38%.
This means → every additional yuan of sales is yielding significantly more profit than a year ago, driven by a structural tilt toward high-margin innovative drugs.
Adjusted net profit came in at RMB 6.243 billion, up 11.70%; basic EPS was RMB 1.05.
How much did innovative drugs contribute — and what shifted inside the mix?
Innovative-drug sales totalled RMB 13.871 billion, up 17.05% YoY, now accounting for 64.59% of pharmaceutical revenue.
In plain terms = nearly two-thirds of what Hengrui sells is now innovative drugs — legacy generics are no longer the backbone.
Oncology innovators brought in RMB 9.865 billion (+3.13%); non-oncology innovators generated RMB 4.006 billion (+75.36%). This reflects a clear hand-off: oncology growth is slowing while non-oncology products are emerging as the new engine.
How much real cash has licensing-out delivered?
Out-licensing — selling overseas rights to self-developed drugs to multinational pharma companies — generated RMB 2.781 billion in recognised revenue, up 31.12% YoY.
The main contributors were GlaxoSmithKline (GSK) and Bristol-Myers Squibb (BMS), recognising revenue based on performance milestones, plus milestone payments on select licensed products.
Hengrui received RMB 4.343 billion in actual cash during the period, largely the USD 600 million upfront payment from BMS. This means → the licensing business is not just paper revenue — real money has hit the bank.
How big is the R&D bill — and where is the money going?
Total R&D spending reached RMB 7.146 billion, of which RMB 5.423 billion was expensed.
In plain terms = for every RMB 100 of revenue, Hengrui ploughs roughly RMB 29 back into R&D — among the highest ratios in China's pharma sector.
This reflects a deliberate strategy: sustain heavy R&D to keep the innovative-drug pipeline deep, stockpiling future revenue drivers.
What should investors watch next?
Whether non-oncology innovators can sustain their 75% growth clip — if this line slows, the overall innovative-drug story loses its strongest momentum.
The pacing of out-licensing milestone payments — whether signed mega-deals trigger their next tranche on schedule directly affects earnings visibility.
This means → whether Hengrui's profit quality is truly "sustainable" hinges not on today's numbers but on where these two variables head from here.
市场有风险，内容仅供研究参考，不构成投资建议。